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ABSTRACT     
A large fraction of human tumors carry inactivating mutations in the TP53 tumor 
suppressor gene. Approximately 75% of these mutations are missense mutations and 
around 10% are nonsense mutations. TP53 inactivation allows evasion of cell death and 
rapid tumor progression. Restoration of wild type p53 protein expression in tumor cells can 
suppress tumor growth in vivo. Missense mutant p53 is often expressed at high levels in 
tumors. Therefore, mutant p53 is a promising target for novel targeted cancer therapy.  
APR-246 (PRIMA-1Met) is a low molecular compound previously discovered in our 
group. We have shown that APR-246 is converted to methylene quinuclidinone (MQ), a 
potent electrophile and Michael acceptor, binding covalently to cysteines in p53. MQ 
promotes refolding of mutant p53 to wild type conformation and restores normal function 
to mutant p53, resulting in induction of apoptosis and inhibition of xenograft tumor growth 
in mice. However, the underlying mechanism is not fully elucidated. APR-246 is currently 
tested in a phase II clinical trial in high-grade serous ovarian cancer. 
In paper I, we show that APR-246, via MQ, targets the Sec residue in the redox enzyme 
TrxR1 and inhibits the reducing activity of both recombinant TrxR1 in vitro and cellular 
TrxR1 in cells independently of p53 status. The inhibited TrxR1 maintains its ability to 
oxidase NADPH, which contributes to oxidative stress and cell death induced by APR-246. 
In paper II, we have confirmed the ability of aminoglycosides to induce translational 
readthrough of nonsense mutant TP53 and also shown that combination treatment with 
aminoglycosides and p53-Mdm2 inhibitors such as nutlin can enhance levels of full-length 
p53 and p53 activity in tumor cells carrying TP53 nonsense mutation. 
In paper III, we through data mining have identified 28 compounds with potential ability to 
target nonsense mutant TP53-carrying cancer cells. Among these, the known anticancer 
drug 5-FU and 5 other compounds were shown to induce full-length p53 protein in 
nonsense mutant TP53-carrying cancer cells. Full-length p53 protein induced by 5-FU is 
transcriptionally active as assessed by upregulation of several p53 target genes. 
In paper IV, we identified 65 compounds, from high-throughput screening and FACS-based 
screening of chemical libraries as candidate readthrough-inducing compounds (CRICs). 
Among these, 7 compounds were shown by Western blotting to induce full-length p53 
protein in nonsense mutant TP53-carrying tumor cells. 
In conclusion, our study reveals that the missense mutant p53-reactivating compound APR-
246 inhibits TrxR1 and converts the enzyme to an NADPH oxidase. We have also shown 
that combination treatment with p53-Mdm2 inhibitors enhances the ability of 
aminoglycosides to restore expression and function of full-length p53 in cancer cells with 
nonsense mutant TP53. Furthermore, we identified 5-FU and several novel compounds as 
compounds that can rescue expression of full-length p53 in tumor cells with nonsense 
mutant TP53. Our studies shed further light on the mechanism underlying APR-246 
induced cancer cell death and raise possibilities for nonsense mutant TP53-targeted cancer 
therapy in the future. Our results may ultimately facilitate the development of novel 
treatment for tumors carrying missense or nonsense mutant TP53.  
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1 INTRODUCTION  
1.1 CANCER 
Cancer, one of the leading causes of morbidity and mortality worldwide, is a collection of 
diseases involving abnormal and uncontrolled cell growth. Malignant tumors invade and 
spread to other organs and form distant metastasis. Cancers, classified according to the their 
primary site of origin, can arise from any tissues and any specialized cell types throughout the 
body (Weinberg, 2007;Torre et al., 2015). Approximately 14.1 million new cases of cancer 
occurred worldwide 2012, and an estimated 23.6 million new cases in 2030 worldwide (Bray 
et al., 2012).  
There are more than 100 types of cancers, such as brain cancer (glioma), breast cancer, colon 
cancer, and renal cancer. All these different types of cancers share 10 common features 
defined as the Hallmarks of cancer: 1) sustaining abnormal proliferative signaling; 2) evading 
growth suppressors such as inactivation of tumor suppressors p53 and Rb; 3) avoiding 
immune destruction; 4) enabling unlimited replicative potential; 5) tumor-promoting 
inflammation supplying bioactive molecules to the tumor microenvironment contribute to 
multiple hallmark capabilities; 6) activating invasion and metastasis with the consequence that 
cancers spread to other organs; 7) inducing angiogenesis to better supply tumors with nutrients 
and oxygen; 8) genome instability and mutation; 9) resisting cell death, for example 
programmed cell death (apoptosis); and 10) abnormal cellular energy metabolism (Hanahan 
and Weinberg, 2011).  
 
1.2 ANTI-CANCER THERAPY  
Surgery, radiation therapy, conventional chemotherapy, and combination of radiation and 
bone marrow transplantation are the most well-known and established cancer therapies. 
Hormone therapy, immunotherapy and targeted therapy are more recently developed cancer 
treatments. Hormone therapy slows or stops the growth of breast and prostate cancers that use 
hormones to grow.  Immunotherapy boosts the immune system to fight cancer. Targeted 
cancer therapy, involving small molecule drugs, monoclonal antibodies and immunotoxins 
targets specific proteins involved in tumor generation and progression and interferes with 
tumors grow and spread throughout the body (Baudino, 2015).  
For example, recently approved immune checkpoint inhibitors: ipilimumab, nivolumab, and 
pembrolizumab have shown great anti-tumor effect in melanoma, lung cancer and renal 
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cancer. (Karlsson and Saleh, 2017;Kazaz and Oztop, 2017;Ross and Jones, 2017). Nivolumab 
and pembrolizumab target PD-L1 on tumor cells, while ipilimumab targets CTLA-4 on T 
cells, inhibiting PD-L1 and CTLA-4 interaction leading to activation of a T cell antitumor 
response (Karlsson and Saleh, 2017).  
 
1.3 THE P53 TUMOR SUPPRESSOR    
1.3.1 Discovery of p53 
In 1979, p53 was first identified as a cellular protein physically complexed with SV40 virus 
large T-antigen, as shown by co-immunoprecipitation with anti-large T antibodies. The protein 
was named as p53 because the molecular mass was estimated to around 53 kDa on the basis of 
its migration in SDS-polyacrylamide gels, even though later the actual molecular mass of the 
human p53 protein was shown to be only 43.7 kDa; mouse p53 is even smaller (Lane and 
Crawford, 1979;Linzer and Levine, 1979;Levine and Oren, 2009). At the beginning, TP53 
was considered an oncogene due to p53 overexpression in various tumors and the ability of 
p53 cDNA to transform cells together with mutant HRAS. However, subsequent studies 
revealed that the p53 cDNA used in many experiments was in fact a mutant version of p53. 
Moreover, DNA sequencing of TP53 in colorectal cancer and other tumors demonstrated 
frequent mutations.  Thus, it became clear that wild type p53 is not an oncogene but rather a 
potent tumor suppressor gene (Levine and Oren, 2009).  
 
1.3.2 Structure of p53 
The TP53 gene, located on the short arm of chromosome 17 (17p13.1), contains 11 exons 
with a non-coding exon 1 and two cryptic exons (9β and 9γ). The TP53 gene encodes nine 
different mRNAs due to its alternative promoters at the N-terminus and alternative splicing 
at intron 2 and intron 9 (Joruiz and Bourdon, 2016). So far these nine different p53 mRNAs 
have been shown to encode 12 different p53 protein isoforms in humans (Bourdon et al., 
2005;Marcel et al., 2010;Joruiz and Bourdon, 2016).  
The wild type full-length p53 protein, with 393 amino acid residues (aa), is composed of two 
transactivation domains (TA1 and TA2), a proline-rich domain (PRD), a DNA binding 
domain (DBD), a nuclear localization signal (NLS), a oligomerisation domain (OD) and a 
regulatory domain (RD) (Joruiz and Bourdon, 2016).  
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Figure 1. Schematic drawing of p53 with its various functional domains. TA1, transactivation 
domains 1; TA2, transactivation domains 2; PRD, proline-rich domain; DBD, DNA binding domain; 
NLS, nuclear localization signal; OD, oligomerisation domain; NES, nuclear export signaling; RD, 
regulatory domain.  
  
As shown in Figure 1, TA1 and TA2, located at N-terminus, are required for interaction with 
the transcriptional co-activators or co-repressors. This region is also critical for binding with 
MDM2. The proline rich domain (PRD) is important for the apoptotic activity of p53. The 
central core of p53 comprises the DNA binding domain (DBD), responsible for the specific 
DNA-binding function of p53, is critical for p53 –dependent transactivation function. The 
Nuclear localization signal (NLS) is essential for nuclear localization of p53. In the C-
terminus of p53, the oligomerisation domain (OD) regulates the teramerization process of 
p53, which is required for p53-dependent transactivation and p53-mediated growth 
suppression. The regulatory domain (RD), including a nuclear export-signaling sequence, is 
shown to play an important role in p53-mediated apoptosis, transcriptional regulation and 
DNA damage recognition (Choisy-Rossi et al., 1999;Batinac et al., 2003;Joerger and Fersht, 
2010;Joruiz and Bourdon, 2016). 
 
1.3.3 p53 activation 
Under normal conditions, p53 protein levels are low, mainly due to its inhibitor mouse 
double-minute 2 (MDM2) and mouse double-minute 4 (MDM4). MDM2, also known as 
human double-minute 2  (HDM2) in human, is an E3 ubiquitin ligase which targets N-
terminus of p53, resulting in inhibition of transactivation domains as well as ubiquitin-
dependent proteasomal degradation of p53. MDM4, also known as MDMX, has similar 
structure as MDM2, but without E3 ligase activity of its own. It binds to the N-terminus of 
p53 and inhibits p53 transactivation domains. However, MDM4 forms heterocomplexes 
with MDM2 and enhance p53 ubiquitination and degradation mediated by MDM2 (Brooks 
and Gu, 2006;Meek, 2015). 
 Various types of cellular stress, such as DNA damage, oncogene-induced hyper-
proliferation, ("oncogenic stress"), oxidative stress, hypoxia, ultraviolet (UV) radiation, and 
viral infection, stabilizes p53 through releasing it from MDM2-mediated inhibition. ATM 
TA2	TA1	 PRD	 DBD	 NLS	 OD	
1									40										62									94																																																																		291						325								357											393	
p53	 NES	 RD	
N	 C	
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(Ataxia telangiectasia mutated) and/or ATR (Ataxia telangiectasia and rad3 related) are 
activated in response to double and single-strand DNA breaks, respectively, leading to p53 
phosphorylation and upregulation (Meek, 2015). Oncogene expression and abnormal cell 
proliferation stimulate the levels of alternative reading frame (ARF) protein, leading to p53 
upregulation through direct binding to MDM2 (Meek, 2015). Besides, aberrant cell 
proliferation due to oncogene activation leads to a DNA damage response that involves p53 
activation and forms a barrier against tumor development (Bartkova et al., 2005;Bartek et 
al., 2007). 
 
1.3.4 p53 regulation 
p53 activity is regulated through various mechanisms including protein-protein interactions, 
post-translational modifications (PTMs), expression of p53 isoforms and cross-talking 
pathways. Apart from MDM2 and MDM4, which have been described previously, p53 can 
also be regulated by various proteins through protein-protein interactions. p53 can also be 
regulated by a wide range of PTMs, including ubiquitylation, phosphorylation, acetylation, 
methylation and sumoylation. So far, 12 different p53 isoforms have been shown to be 
expressed in different human cells and tissues. All these different p53 isoforms can undergo 
different PTMs and take part in protein-protein interactions. This creates a complex network 
that regulates p53 function (Meek, 2015).  
 
1.3.5 p53 functions  
1.3.5.1 Cell cycle arrest and DNA repair 
DNA damage activates cell cycle arrest, which allows DNA repair. DNA damage activates 
ATM/ATR pathway, resulting in activation of p53 and transactivation of its target genes and 
subsequent G1 and G2 arrest. p21 (CDKN1A), the first p53 target gene to be discovered, 
encodes the cell cycle inhibitor p21. Induction of p21 expression causes both G1 and G2 
arrest, as result of inhibition of cyclin E/CDK2 and cyclin B/CDK1 (Bunz et al., 1998;Li 
and Ho, 1998).  Other p53 target genes, including 14-3-3σ, can also regulate cell cycle arrest 
(Hermeking et al., 1997). In addition, p53 is involved in base excision and nucleotide 
excision repair (Gotz and Montenarh, 1996;Soddu and Sacchi, 1997;Li and Ho, 1998).  
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1.3.5.2 Apopotosis 
p53 induces expression of a variety of genes involved in both extrinsic (death receptor) 
pathway and intrinsic pathway. Several of p53 target genes such as death receptor FAS, DR4 
and DR5 are involved in extrinsic apoptotic pathway. FASL and TRAIL ligands bind to the 
FAS, DR4 and DR5 death receptors, triggering the recruitment of FAS-associated death 
domain (FADD), leading to activation of caspase-8, resulting in activation of effector 
caspases and apoptotic response (Fridman and Lowe, 2003;Amaral et al., 2010).  
The intrinsic apoptotic (mitochondria) pathway, regulated by Bcl-2 family proteins, involves 
mitochondrial depolarization, translocation of cytochrome C from the mitochondrial 
intermembrane into the cytoplasm, apoptosome formation and activation of caspases. Bcl-2 
family proteins can be divided into three groups: the anti-apoptotic proteins with structure 
similar to Bcl-2, e.g. Bcl-xL; the pro-apoptotic proteins structurally related to Bcl-2, e.g. 
Bax and Bak; the third group of the proteins are pro-apoptotic with only BH-3 domain called 
“BH3-only” proteins, e.g. Puma and Noxa. Several of p53 target genes are involved in this 
pathway, for example BAX, PUMA and NOXA. Puma and Noxa help Bax translocation to 
the surface of mitochondria. Bax oligomerizes and forms complex with Bax on the surface 
of mitochondria, as well as p53 forms complex with cyclophilin D in the mitochondrial 
inner membrane. These changes result in disruption of mitochondrial membranes and release 
of pro-apoptotic proteins such as cytochrome c and apoptosis-inducing factor (AIF) from 
mitochondria, which eventually activate caspase activity and apoptosis (Gotz and 
Montenarh, 1996;Li and Ho, 1998;Fridman and Lowe, 2003;Mihara et al., 2003;Amaral et 
al., 2010;Meek, 2015).  
 
1.3.5.3 Senescence 
Cellular senescence, a form of irreversible cell cycle arrest, is induced by loss of replicative 
ability due to various stresses including dysfunctional telomeres, DNA damage, oxidative 
stress, oncogene activation and nutrients starvation. The senescent cells with a large and 
flattened morphology are still metabolically active, but do not proliferate. Several of p53 
target genes including p21 play important role in activation of senescence. Senescence is 
induced by many chemotherapeutic agents that cause DNA damage and p53 activation. 
However, impairment of p53 function can inhibit drug-induced senescence and result in 
tumor progression. The ability of p53 to regulate senescence may contribute to p53-
mediated tumor suppression in vivo (Qian and Chen, 2010;2013).  
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1.3.5.4 Ferroptosis 
p53 also regulates ferroptosis, an iron-meditated, caspase-independent programmed cell 
death requiring the accumulation of lipid peroxides and oxidative stress. This pathway was 
shown to be controlled by glutathione peroxidase 4 (GPX4), a glutathione-regulated lipid 
repair enzyme and to be regulated by p53 target genes SLC7A11, SAT1 and GLS2. p53 
transcriptionally repress SLC7A11, a component of the cystine/glutamate antiporter, system 
Xc-, resulting in reduced cystine import, leading to decreased glutathione production and 
increased reactive oxygen species (ROS). p53 can also transcriptionally activate glutaminase 
2 (GLS2), and SAT1, resulting in increased ROS and lipid peroxides that are required for 
ferroptosis. Ferroptosis is a critical component of p53-mediated tumor suppression (Murphy, 
2016;Gnanapradeepan et al., 2018).  
 
 
 
Figure 2. p53 activation and signaling pathways. 
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1.3.5.5 Metabolism 
p53 is also involved in regulation of oxidative phosphorylation, glucose metabolism and 
lipid metabolism. Wild type p53 regulates cell metabolism by favoring mitochondrial 
respiration over glycolysis, mainly through promoting oxidative phosphorylation by 
transactivation of cytochrome c oxidase subunit 2 (SCO2), promoting glutaminolysis for 
mitochondrial respiration by transactivation of Glutaminase 2 (GLS2), and suppressing 
glycolysis by transactivation of glycolysis inhibitors RRAD and TIGAR, as well as 
transcriptionally repressing the glucose transporters GLUT1 and GLUT4. In addition, p53 
also suppressing glucose metabolism through directly binding and inhibition of the enzyme 
glucose-6-phosphate dehydrogenase (G6PDH) (Vousden, 2009;Gnanapradeepan et al., 
2018). 
WT p53 promotes fatty acid oxidation through transactivation carnitine palmitoyltransferase 
1C (CPT1C) and Lipin 1 (LPIN1) while suppressing fatty acid synthesis through inhibition 
of G6PDH and sterol regulatory element-binding proteins (SREBP) via protein-protein 
interaction. Therefore, p53 and many of its target genes are involved in metabolic disease, 
such as obesity and diabetes (Vousden, 2009;Gnanapradeepan et al., 2018).  
 
1.3.5.6 Differentiation and Fertility 
p53 suppresses stem cell self-renewal after DNA damage and induce stem cell                                
differentiation, therefore eliminates tumorigenesis. Activation of p53 results in inhibition of 
reprogramming of both normal and cancer cells to induced pluripotent stem cells (iPSCs). 
p53 regulates embryonic implantation through transcriptional regulation of leukemia 
inhibitory factor (LIF). Loss of p53 genes in female mice leads to a significant decrease in 
fertility (Rotter et al., 1994;Li et al., 2013). Besides, p53 is also involved in inhibition of 
angiogenesis and metastasis (Song et al., 2015). 
 
1.3.6 TP53 inactivation in cancer 
TP53 inactivation plays an key role in tumorigenesis and tumor progression. p53 
inactivation by TP53 mutation occurs in a large fraction of human tumors, as shown in 
Figure 2 (Cerami et al., 2012;Gao et al., 2013).  
90% of TP53 mutations are localized in the p53 core domain (residue 100 to 300). About 
75% of TP53 alterations are missense mutations, resulting in single amino acid substitutions 
in p53, leading to the synthesis of stable mutant proteins (Soussi and Wiman, 2015). It has 
  20 
been shown that the gain-of-function of mutant p53 enhances cancer progression (Acin et 
al., 2011;Zhou et al., 2014). TP53 mutations are often but not always associated with poor 
therapy response and survival (Gudkov and Komarova, 2003;Robles and Harris, 2010;Said 
et al., 2013) 
 
Figure 3. TP53 alteration frequency in human cancer genomics.  Recorded in cBioPortal for 
cancer genomics. (http://www.cbioportal.org/index.do) 
 
Approximately 10% TP53 alterations are nonsense mutations, changing an amino acid 
codon to a premature termination codon (PTC) (TAG, TGA, or TAA), resulting in 
premature termination of the protein translation process and expression of unstable truncated 
proteins (Linde and Kerem, 2008). In addition, mRNAs with PTCs are usually expressed at 
low levels due to degradation by nonsense-mediated decay (NMD) (Isken and Maquat, 
2008;Lykke-Andersen and Jensen, 2015). R213X is the most common TP53 nonsense 
mutation, representing around 19% of all TP53 nonsense mutations and approximately 2 % 
of all TP53 mutations in human tumors.  
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In addition to TP53 mutation, wild type p53 can be inactivated in tumors by the cellular 
antagonists MDM2 and MDM4, and by viral proteins such as HPV E6, SV40 large T and 
adenovirus E1B55K (Levine, 2009;Tsai et al., 2009).  
 
1.4 P53-TARGETED CANCER THERAPY       
1.4.1 Wild type p53-targeted cancer therapy    
p53 inactivation is a universal feature of human cancer cells. Around 50% of cancers carry 
wild type p53 which can be inactivated through various mechanisms. The E3 ubiquitin 
ligase MDM2 is the one of the most important regulators of p53. Negative regulation of wild 
type p53 through overexpression of MDM2/MDM4 frequently occurs in human cancers 
with wild type p53. Many compounds were identified to target the interaction between wild 
type p53 and MDM2/MDM4. For example, nutlins and RITA have been shown to inhibit 
the interaction between MDM2 and p53, and induce p53 target genes as well as p53-
mediated cell cycle arrest and apoptosis (Issaeva et al., 2004;Doggrell, 2005;Trino et al., 
2016). SJ-172550 inhibits the interaction between MDM4 and p53, leading to p53-
dependent apoptosis (Bista et al., 2012). Besides, antisense oligos and siRNAs have been 
used to inhibit MDM2 and HPV E6 to induce rapid and effective p53 response (Jiang and 
Milner, 2002;Zhang et al., 2005). Several p53-Mdm2 inhibitors are currently or have been 
tested in clinical trials, including RG7112, GO5503781, MI-773 and DS-3032b (Khoo et al., 
2014). 
1.4.2 Missense mutant p53-targeted cancer therapy    
 
 
 
Figure 4. APR-246 is converted to MQ inside cells. Adapted from Bykov et al., Cell Cycle 2009. 
APR-246 
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Around 50% of human tumors carry TP53 mutations. As descried above, the majority of 
TP53 (75%) alterations are missense mutations. A lot of efforts have been made to identify 
small molecules that can reactivate mutant p53. APR-246 is the most well-studied 
compound in this category. The small molecule PRIMA-1 was identified in cell-based 
screen of the National Cancer Institute (NCI) Diversity set of compounds for substances 
inducing mutant p53-dependent growth suppression in tumor cells. PRIMA-1 induced p53 
target genes and p53-mediated apoptosis in cancer cells (Bykov et al., 2002a;Bykov et al., 
2002b). APR-246 (PRIMA-1Met) is a more potent analog of PRIMA-1. Both APR-246 and 
PRIMA-1 are converted to methylene quinuclidinone (MQ). MQ is a potent electrophile and 
Michael acceptor and responsible for the biological effects of APR-246.  APR-246 inhibites 
the growth of cancer cells in culture as well as xenograft tumors in mice (Bykov and 
Wiman, 2014). Furthermore, APR-246 synergizes with DNA-damaging agents such as 
adriamycin and cisplatin to induce apoptosis in cancer cells (Bykov et al., 2005;Fransson et 
al., 2016). Although the exact mechanism is not fully understood, MQ binding to cysteines 
in p53 promotes refolding of p53 to a "wild type-like" conformation. Cysteine 277 is a prime 
binding site for MQ and required for MQ-mediated thermostabilization of the p53 core 
domain (Zhang et al., 2018). 
APR-246 has been investigated in a phase I/IIa clinical trial in 22 patients with prostate 
cancer and different types of hematologic malignancies (clinicaltrials.gov Identifier: 
NCT00900614)(Medicine, 2011).  The treatment was well tolerated. The most common 
adverse effects were fatigue, dizziness, headache and confusion. This study and an extension 
study with another 10 patients also showed clinical effects in five out of six patients carrying 
mutant TP53 (Lehmann et al., 2012).  
 Currently, APR-246 is undergoing a phase II proof-of-concept randomized clinical trial in 
patients with recurrent high-grade serous ovarian cancer, a tumor type with a TP53 mutation 
frequency of around 95% (Clinical-Trials.gov Identifier: NCT02098343). The study 
investigates APR-246 in combination treatment with carboplatin and pegylated doxorubicin. 
Meanwhile, a phase Ib/II clinical trial of APR-246 in combination with the cytosine 
analogue azacitidine in patients with myelodysplastic syndrome (MDS) carrying TP53 
mutations has been initiated. In addition, a phase Ib/II clinical trial of APR-246 in 
combination with cisplatin and 5-fluorouracil in patients with esophageal cancer has started. 
Several other small molecules have been shown to restore wild type p53 conformation and 
function to missense mutant p53, including MIRA, PK11007, ZMC1 and stictic acid 
(reviewed by Bykov et al., 2018) 
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1.4.3 Nonsense mutant p53-targeted cancer therapy     
 
 
 
 
 
 
 
Figure 5. The effect of readthrough drug aminoglycoside on protein translation. 
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mRNAs pair-match with anticodons on tRNAs, linking amino acids into proteins until 
arriving at the stop codons. However, when a ribosome encounters a PTC due to nonsense 
mutation, the translation process is terminated prematurely, due to no tRNA pair-match with 
PTC. At the same time eukaryotic release factors (eRF1 and eRF3) are recruited and 
unstable truncated protein is released (Linde and Kerem, 2008). mRNAs containing 
premature termination codons (PTCs) activate nonsense-mediated mRNA decay (NMD) 
(Isken and Maquat, 2008;Lykke-Andersen and Jensen, 2015). Nonsense mutations are not 
only causative in genetic diseases such as cystic fibrosis and Duchenne muscular dystrophy, 
but also common in various types of tumors (Mort et al., 2008;Prokofyeva et al., 2013;Wei 
et al., 2014).  
Induction of translational readthrough is an interesting potential therapeutic strategy for 
genetic diseases and cancers caused by nonsense mutations. Aminoglycoside antibiotics 
G418 and gentamicin have been shown to suppress PTCs in a variety of genes, including 
TP53, leading to upregulation of p53 target genes and p53-dependent cell death (Floquet et 
al., 2011;Bidou et al., 2017). Gentamycin B1, a minor gentamicin component, was shown to 
be more potent readthrough inducer (Baradaran-Heravi et al., 2017). However, treatment 
with aminoglycosides can lead to severe nephrotoxicity and ototoxicity, which makes them 
less attractive for long-term treatment at high doses.  
There are also a few non-aminoglycosides readthrough-inducing compounds. The 
oxadiazole Ataluren (PTC124) was identified in a high-throughput screen using a firefly 
luciferase-based readthrough reporter. However, its molecular mechanism remains 
controversial (Sheridan, 2013) and data suggest that Ataluren stabilizes the luciferase protein 
(Auld et al., 2010). Clinical studies with Ataluren in cystic fibrosis and Duchenne muscular 
dystrophy have not shown any striking beneficial effect (Zainal Abidin et al., 2017). 
Nonetheless, Ataluren recently obtained conditional approval by the European Medicines 
Agency (EMA) for treatment of Duchenne muscular dystrophy (Mullard, 2014).  
NMD inhibitors NMDI14 and amlexanox were also shown to promote readthrough of PTCs.  
In addition, combination of readthrough reagent and NMD inhibitors showed synergistic 
effects on restoration of full-length p53 protein as well as induction of p53 target gene 
(Gonzalez-Hilarion et al., 2012;Martin et al., 2014).  
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1.5 REDOX HOMEOSTASIS AND CANCER THERAPY  
Redox homeostasis is the balance between reactive oxygen species (ROS) generation and 
ROS elimination by antioxidant systems in cells. Regulation of redox homeostasis plays a 
vital role in maintaining normal cellular functions and ensuring cell survival (Gorrini et al., 
2013;Tong et al., 2015).  
Cancer cells are characterized by elevated aerobic glycolysis (the Warburg effect) and high 
levels of oxidative stress due to increased ROS generation in order to hyper-activate cell 
signaling pathways that promote cancer cell proliferation, survival and adaptation to the 
tumor microenvironment, e.g. hypoxia. These high levels of ROS are counteracted by 
elevated antioxidant systems in cancer cells (Gorrini et al., 2013;Glasauer and Chandel, 
2014;Tong et al., 2015).  
The thioredoxin (Trx) system and the glutathione (GSH) system are the two major systems 
that maintain cytosolic redox homeostasis. The Trx system comprises of Trx, thioredoxin 
reductase (TrxR) and the cofactor NADPH, and the GSH system consists of GSH, 
glutathione reductase (GR), glutaredoxin(Grx), and NADPH. Nuclear factor erythroid 2-
related factor 2 (NRF2) is the master regulator of antioxidant responses which regulates the 
expression of multiple enzymes involved in several antioxidants pathways including both 
Trx and GSH systems as well as other antioxidant enzymes, e.g. SOD (Cebula et al., 
2015;Xu et al., 2016).  
TrxR is the only known enzyme to reduce Trx, with three isoforms in human including 
TrxR1, TrxR2 and TrxR3. TrxR1 is the major form of TrxR expressed in most tissues with 
the location mainly in cytosol, and TrxR2 is mainly located in mitochondria. TrxR3 is only 
found in various tissues at very low levels (Mustacich and Powis, 2000;Conrad et al., 
2004;Cebula et al., 2015).   
Mammalian TrxR1 exists as homodimer with a Sec in its C-terminal active domain in each 
monomer. During the catalytic process, the N-terminal active site of TrxR1 oxidases 
NADPH and transfers electrons to the C-terminal active site of the other monomer. The 
reduced C-terminal active site with a selenothiol motif subsequently reduces various 
substrates including oxidized Trx, as well as synthesized chemical dithionitrobenzoic acid  
(DTNB). Reduction of DTNB results in production of thionitrobenzoic acid (TNB), whose 
color can be measured at 412nm with a plate reader or spectrophotometer. However, some 
substrates such as certain quinones, e.g. organic compound 5-hydroxy-1, 4-naphthoquinone 
  26 
 (juglone) can be reduced directly by the N-terminal active site of TrxR1 (Conrad et al., 
2004;Peng et al., 2012;Peng et al., 2013;Xu et al., 2016).  
TrxR1 through reduced Trx1 plays a very important role in DNA synthesis and protection 
against redox stress. Besides, TrxR1 has also been shown to regulate p53 redox status. 
Inhibition of TrxR1 in yeasts and in human cells was shown to induce disulfides in p53 and 
inactivate DNA binding but not affect p53 protein levels. In addition, TrxR1 is very 
important for certain signaling events required for embryonic development. Knockdown of 
TrxR1 through gene deletion results in embryonic death. However, knockdown of TrxR1 in 
cells and tissues does not necessary exhibit apparent phenotype. The DNA synthesis and 
antioxidant defense in TrxR1 deficient cells is compensated by elevated NRF2 and GSH 
systems (Mustacich and Powis, 2000;Hedstrom et al., 2009;Bykov et al., 2016). 
 
 
 
 
Figure 6. Gain of pro-oxidant function of TrxR1 after modification by an electrophile at Sec C-
terminal active motif. Adapted from Cassidy et al.,Carcinogenesis 2006. 
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Mammalian TrxR1, in its C-terminal active domain, contains selenocysteine with low pKa 
and higher nucleophilicity that is an easily accessible target for electrophiles. TrxR1, with 
Sec inhibited in C- terminal active domain by electrophiles such as cisplatin while NADPH 
oxidase activity preserved at N-terminal active domain, results in not only inhibition of 
reducing activity but also gain of pro-oxidant function that induces massive ROS production 
and caspase activation which ultimately leads to extensive cancer cell death. Cancer cells 
usually express higher level of TrxR1, and targeting TrxR1 shows higher toxicity in cancer 
cells rather than in normal cells, which make it a promising anticancer strategy (Peng et al., 
2012;Peng et al., 2013;Cebula et al., 2015).  
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2 AIMS OF THE THESIS  
The general aims of the thesis were to identify novel compounds that can induce 
translational readthrough of nonsense mutant TP53 and further investigate the molecular 
mechanisms of the missense mutant p53-targeting compound APR-246. These studies may 
open avenues for novel p53-targeted cancer therapy. 
 
Specific aims 
Paper I 
To investigate whether APR-246 targets the selenoprotein thioredoxin reductase 1 (TrxR1) 
and whether this contributes to APR-246-induced tumor cell death.  
 
Paper II 
To explore combination treatment with aminoglycosides and Mdm2 inhibitors to induce 
translational readthrough of nonsense mutant TP53.  
 
Paper III 
To identify novel nonsense mutant TP53-targeting compounds through data mining. 
 
Paper IV 
To perform high-throughput screening to identify novel compounds that induce 
translational readthrough of nonsense mutant TP53. 
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3 RESULTS AND DISCUSSION  
3.1 PAPER I 
APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a 
dedicated NADPH oxidase 
We previously showed that both PRIMA-1 and APR-246 are converted into the active 
compound MQ that covalently binds to Cys residues in mutant p53 and restore wild type 
p53 conformation and function to mutant p53, leading to induction of p53 target genes and 
p53-mediated cancer cell death. We would like to investigate whether MQ also has other 
targets in tumor cells. One potential target high related to cancer is thioredoxin reductase 
1(TrxR1), an important regulator of redox balance in cells, which catalyzes the reduction of 
thioredoxin using NADPH. Since mammalian TrxR1 contains a selenocysteine (Sec) in its 
active motif and Sec is significantly more reactive than Cys due to its higher nucleophility. 
To investigate whether APR-246 targets TrxR1 and affects its function, we first tested if 
APR-246 affects the function of TrxR1 in vitro. It revealed that both pre-heated APR-246 
and MQ strongly inhibited the reducing activity of TrxR1 while maintained its ability to 
consume NADPH. In addition, the Sec to Cys variant of TrxR1 was much more resistant to 
inhibition induced by APR-246 and MQ, indicating that the Sec residue of the TrxR1 was 
the primary target of MQ during the inhibition of the TrxR1.  
To analyze if APR-246 also inhibits the activity of TrxR1 in cells, various cancer cells with 
different p53 status were treated with APR-246 at different concentrations for different 
times periods. This showed that TrxR1 activity strongly decreased by APR-246 treatment 
independent of p53 status. 
In order to test whether the inhibition of TrxR1 contributes to cell death induced by APR-
246, we used siRNAs to downregulate the expression of TrxR1. Data revealed that APR-
246 induced substantial cell death in cancer cells with p53 missense mutation but much 
milder cell death in p53 null cancer cells. Knockdown of TrxR1 did not induce any 
substantial cell death by itself. However, it partially rescued cell death induced by APR-246 
in both cell lines, independent of p53 status. These results suggested that mutant p53 was 
the main target for APR-246 induced cancer cell death, and TrxR1 was the one of the 
secondary targets that contributes to APR-246 mediated cancer cell death. 
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How the inhibition of TrxR1 by APR-246 affected reactive oxygen species (ROS) 
generation was also examined. The results uncovered that APR-246 strongly induced 
production of ROS in cancer cells with p53 missense mutation while it only mildly 
upregulated ROS production in p53 null cancer cells. Knockdown of TrxR1 by siRNA did 
not induce substantial ROS generation by itself, but strongly attenuated ROS production 
induced by APR-246. The results indicated that TrxR1 contributed significantly to ROS 
induced by APR-246. 
To sum up, our study uncovered that TrxR1 is a target of APR-246, which contributes to 
APR-246-induced ROS induction and cancer cell death. Inhibition of TrxR1 by APR-246 
in addition to its ability to restore wild type function to missense-mutated p53 produced an 
additive effect on disrupting the cellular redox balance and accelerated apoptosis signaling 
cascade. Targeting both TrxR1 and missense mutant p53 may also reduce the risk of 
resistance to treatment.  
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3.2 PAPER II  
Synergistic rescue of nonsense mutant tumor suppressor p53 by combination 
treatment with aminoglycosides and Mdm2 inhibitors.  
The tumor suppressor p53 is frequently inactivated by TP53 mutations. Approximately 
10% of TP53 mutations are nonsense mutations resulting in the expression of unstable 
truncated p53 proteins. Aminoglycosides G418 and gentamicin haven been shown by 
previous study to induce readthrough of PTCs and expression of full-length proteins 
including full-length p53. However, the nephrotoxicity and ototoxicity of aminoglycosides 
limit its clinical usage.  
In this study, the ability of aminoglycosides to induce readthough of PTCs in TP53 was 
first examined in HDQ-P1 cell carrying endogenous R213X nonsense mutant p53 and 
H1299 transfected with plasmid containing p53 coding sequence with a nonsense mutation 
at codon 213 or with plasmid containing the first 213 codons of R213X p53 fused in frame 
with the EGFP coding sequence. This showed that G418 induced readthrough of PTC 
(R213X) in all tested cell lines leading to expression of full-length protein p53 as well as 
R213XΔC-EGFP fusion protein. In addition, G418 induced p53 mRNA in a time dependent 
manner. Gentamicin also induced p53 mRNA and expression of full-length p53 protein, 
although much less efficiently.   
To further study whether the full-length p53 protein induced by aminolgycosides in cancer 
cells is transcriptional active, p53 target genes were analyzed at both protein and mRNA 
levels. The results revealed that G418 and gentamicin induce p53 target genes at both 
mRNA and protein levels, indicating the induced full-length p53 protein is transcriptional 
active. 
With the question whether the restored full-length p53 could be further enhanced by 
combination treatments. We analyzed the aminoglycosides in combination with proteasome 
inhibitor bortezomib and p53-Mdm2 inhibitors, including nultin-3a and MI-773. This 
showed that the combination treatments enhanced the expression of full-length p53 protein. 
The combination treatment with nutlin-3a and aminoglycosides showed strongly synergistic 
effect on induction of both mRNA and full-length protein of p53 as well as p53 target 
genes.  
Last but not the least, we explored if the combination treatment potentiates p53 mediated 
cellular response. The results showed that G418 induced nonsense mutant p53 dependent 
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growth inhibition, cell death and cell cycle arrest. G418 in combination with nutlin-3a 
enhanced growth inhibition and showed synergistically enhanced cancer cell death.  
In conclusion, our study demonstrates that combination treatment with aminoglycosides 
and p53-Mdm2 inhibitors provide strong synergistic effects on expression of full-length 
p53 protein, induction of p53 target genes as well as p53-mediated cancer cell suppression. 
This study may contribute to future cancer therapy that targets nonsense mutant TP53 and 
restores wild type p53 anti-cancer activity.  
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3.3 PAPER III     
Rescue of nonsense mutant p53 in human tumor cells by compounds identified 
through data mining 
National Cancer Instituet (NCI) provides data on the growth-inhibition (GI) effect of many 
chemical compounds in 60 different human cancer cells lines. We performed an analysis 
based on NCI-60 database, in order to identify compounds that specifically induce growth 
inhibition in cancer cells with TP53 nonsense mutations rather than cancer cells carrying 
other TP53 mutations or wild type TP53. We identified 28 potential interesting compounds, 
including the known anticancer drug 5-fluorouracil (5-FU), based on analysis of 47,000 
compounds.  
We examined 18 compounds available from NCI out of the identified 28 compounds. The 
results revealed that 5 compounds, designated as MZ21, MZ23, MZ26, MZ30 and MZ32, 
were able to induce full-length p53 protein in cancer cells with p53 nonsense mutation 
R213X.  
Moreover, 5-FU treatment restored substantial expression of full-length p53 in both 
endogenous p53 nonsense-mutant HDQ-P1 cancer cells and cancer cells H1299 R213X, 
H1299 cells stably transfected with plasmid carrying p53-coding sequence with a PTC 
(R213X). 5-FU also induced mRNAs of p53 and p53 target genes in HDQ-P1 and H1299-
R213X cells but not H1299 empty vector cells indicating the p53 target gene induction by 
5-FU is p53-dependent and suggesting that the restored full-length p53 protein is 
transcriptionally active.  
In addition, we also tested 5-FU in H1299 cells transfected with a plasmid carrying only the 
first 213 codons of R213X p53 fused in frame with EGFP (H1299-R213XΔC-EGFP). This 
showed that 5-FU restored expression of p53 R213XΔC-EGFP fusion protein.  
In summary, 5-FU restored expression of full-length p53 protein and p53 transcriptional 
activity in cancer cells with p53 nonsense mutation. However, the underlying mechanisms 
remains unknown. We provide several possible reasons including direct stabilization of p53 
mRNA, stabilization of p53 protein and translational readthrough of PTC. Further study is 
required to elucidate the exact molecular mechanisms. The uncovered ability of 5-FU to 
restore expression of full-length p53 and p53 function in cancer cells carrying TP53 
nonsense mutation may open new therapeutic applications for 5-FU. Several other 
compounds identified from our NCI database mining also showed promising ability to 
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induce expression of full-length p53 in cancer cells with TP53 nonsense mutation. The 
identification of small molecules that can rescue full-length p53 expression in cancer cells 
with nonsense mutant TP53 may ultimately allow the design of novel anticancer drugs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  37 
 
3.4 PAPER IV 
High-throughput screening for identification of novel compounds that induce 
translational readthrough of nonsense mutant p53 
In this study, we first established a high-throughput screening assay based on p53-
immunofluorescence staining in HDQ-P1 breast cancer cells carrying a homozygous 
nonsense mutation in TP53 at codon 213. We screened 33,000 compounds from different 
libraries and selected 47 compounds designated as potential candidate readthrough-
inducing compounds (CRICs). We also screened a library of anti-infectious compounds 
(130 molecules) in HDQ-P1 cells by FACS. We selected 18 compounds that induced more 
p53-positive cells than G418 as CRICs for further study. In total, we selected 65 
compounds as CRICs based on these screens.  
The CRICs were further tested by ELISA in H1299-R213XΔC-FLAG cells and by Western 
blotting in H1299-R213X to confirm their ability of restoring expression of full-length 
protein. Several CRICs including CRIC 3, 44, 45, 47, 50, 53 and 58 induced both fusion 
protein p53 R213XΔC-FLAG in H1299-R213XΔC-FlAG cells and full-length p53 protein 
in H1299-R213X cells. 
The observed ability of CRIC 44, 45, 47, 50, 53 and 58 to induce full-length p53 protein 
expression in H1299-R213X cells is consistent with our previous p53 immunostaining data 
in HDQ-P1 cells. CRIC 44, 45, 47, 50, 53 and 58 induced p53 immunostaining in a dose-
dependent manner in HDQ-P1 cells. Further studies are required to uncover the 
mechanisms underlying the ability to restore expression of full-length p53 in cancer cells 
with TP53 nonsense mutation and to elucidate the biological activity of the restored full-
length p53 protein. We believe that our study will benefit nonsense-mutant p53-targeted 
cancer therapy.  
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4 CONCLUSIONS 
Paper I. In this study, we show that APR-246 converted to MQ inhibits the reducing 
activity of both recombinant TrxR1 in vitro and cellular TrxR1 in cells independent of p53 
status. A Sec-to-Cys variant of TrxR1 is resistant to inhibition induced by APR-246 
indicating that Sec residue is the target of MQ. Inhibited TrxR1 by APR-246 maintains its 
ability to oxidize NADPH resulting in massive ROS induction. Knockdown of TrxR1 
attenuates APR-246-induced ROS induction and cell death independently of p53 status.  
 
Paper II. In this paper, we reveal that aminoglycosides G418 and gentamicin induce strong 
translational readthrough of PTC (R213X) in TP53, which results in expression of 
functional full-length p53 protein leading to induction of p53 target genes as well as p53-
mediated growth inhibition and cell death in cancer cells. More important, the combination 
treatment with aminoglycosides and p53-Mdm2 inhibitors synergistically increases 
expression of full-length p53 protein and largely potentiates p53-mediated biological 
response.   
 
Paper III. In this study, from data mining of the NCI database, we first identified 28 
compounds as potential agents targeting nonsense-mutant p53 cancer cells. Among these, 
the known anticancer drug 5-FU and 5 other compounds without any known anti-cancer 
activity were shown to induce full-length p53 protein in nonsense-mutant p53 cancer cells. 
Full-length p53 protein induced by 5-FU is transcriptionally active as assessed by 
upregulation of several p53 target genes. 
 
Paper IV. In this study, from a high-throughput screening based on p53 immunostaining 
and a FACS based screening, we selected 65 compounds as potential candidate 
readthrough-inducing compounds (CRICs). Among these, 7 compounds were shown to 
induce full-length p53 protein in nonsense-mutant p53 cancer cells. 
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5 FUTURE PERSPECTIVES   
With the aim to identify future nonsense-mutant p53 targeted therapeutic agents with low 
toxicity profile, we did data mining of NCI database and high-throughput screening as well 
as FACS based screening. So far, several compounds including 5-FU were shown to induce 
full-length p53 in cancer cells with TP53 nonsense mutation.  
5-FU restored full-length p53 protein is transcriptionally active as assessed by upregulation 
of p53 target genes in a p53 dependent manner. We would like to further investigate 
whether 5-FU causes p53-mediated cellular response including cell death, cell cycle arrest 
and apoptosis. Except 5-FU, we are not sure if induced full-length p53 protein in cancer 
cells with TP53 nonsense mutation by other compounds is functional. We will further 
investigate this issue.  
The mechanisms underlay induced full-length p53 in cancer cells with TP53 nonsense 
mutation by these compounds are still poorly understood. We provide several possible 
mechanisms. The first possible reason of upregulated full-length p53 expression may be a 
direct stabilization of p53 mRNA through inhibition of nonsense-mediated mRNA decay 
(NMD), a process that normally degrades mRNAs with a PTC. Inhibition of NMD would 
lead to enhanced p53 mRNA levels and possibly higher levels of full-length p53 as a result 
of spontaneous readthrough. The known NMD inhibitor amlexanox has been shown to 
rescue nonsense mutations in TP53, DMD and CFT (Gonzalez-Hilarion et al., 2012).  
Another plausible reason for the observed upregulation of p53 levels could be stabilization 
of full-length p53 due to low levels of spontaneous readthrough. To address this possibility, 
we will test if these compounds can induce p53 expression in cells carrying wild type TP53 
such as HCT116 and MCF7. 
A third possible mechanism for induction of full-length p53 protein by these compounds is 
induction of translational readthrough. It is very important to test if these compounds can 
indeed induce translational readthrough of PTC. To examine this, we will test them in a 
p53-independent context using a relevant reporter construct, such as EGFP or RFP 
containing an internal PTC. Moreover, we will also investigate if these compounds can 
rescue expression of full-length protein from other nonsense mutant genes, e.g. nonsense 
mutant APC or RB1. 
Further studies are required to elucidate which one of these mechanisms, or a combination 
of several, is responsible for induction of full-length p53 by these compounds respectively.  
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If we can confirm one or several compounds with the ability to induce translational 
readthrough of PTCs, We will apply structure-activity relationship (SAR) analysis to 
identify critical chemical structures with the aim of improving readthrough efficacy and 
other features of relevance for drug development.  
Besides, combination treatment with novel readthrough inducing compounds and p53-
Mdm2 inhibitors may also improve readthrough efficacy and thus allow reducing the 
toxicity of the treatment. Our long-term goal is to take the most promising readthrough 
compound and/or combination treatments through preclinical development and ultimately 
clinical trials. 
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